Biologic Specimen and Data Repository Information Coordinating Center
Home > Studies > LaSRS

Resources Available

Specimens and Study Datasets

Materials Available

BRONCHIAL LAVAGE 3,308
LEUKOCYTES 480
PLASMA 236

Study Documents

PDF Data Dictionary (PDF - 371.8 KB)
PDF CRFs (PDF - 1017.9 KB)
PDF Protocol (PDF - 2.5 MB)

Persons using assistive technology may not be able to fully access information in the study documents. For assistance, Contact BioLINCC and include the web address and/or publication title in your message.

If you need help accessing information in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.

Acute Respiratory Distress Network Study 02 (ARDSNet 02) Late Steroid Rescue Study (LaSRS)

Website: http://www.ardsnet.org/
Clinical Trials URL: http://clinicaltrials.gov/ct2/show/...
Study Type: Clinical Trial
Prepared on October 13, 2008
Last Updated on August 24, 2006
Study Dates: 1997-2003
Consent: Restricted Consent
Consent Restrictions: Consent is tiered regarding genetic research.
Commercial Use Restrictions: No
NHLBI Division: DLD
Collection Type: Open BioLINCC Study - See bottom of this webpage for request information

Objectives

Since previous reports suggested that corticosteroids may improve survival, this project was developed as a multicenter, randomized controlled trial of corticosteroids in patients with persistent ARDS.

Background

Persistent acute respiratory distress syndrome (ARDS) is characterized by excessive fibroproliferation, ongoing inflammation, prolonged mechanical ventilation, and a substantial risk of death.

Subjects

180 randomly assigned patients with ARDS of at least seven days duration received either methylprednisolone or placebo in a double-blind fashion. The primary end point was mortality at 60 days.

Conclusions

The results do not support the routine use of methylprednisolone for persistent ARDS despite the improvement in cardiopulmonary physiology. In addition, starting methylprednisolone therapy more than two weeks after the onset of ARDS may increase the risk of death. (NEJM April 20, 2006; Vol 354, No. 16, pp 1671-84)